The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3687-3695

  Zhao, R ^a   Babani, S ^a   Gao, F ^a   Liu, L ^a   Goldman, I D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; METHOTREXATE; PEMETREXED;

ANIMAL CELL; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CELL MEMBRANE TRANSPORT; CROSS RESISTANCE; DRUG TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; LEUCOVORIN; LEUKEMIA L1210; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; MICE; PEPTIDE SYNTHASES; POLYGLUTAMIC ACID; PROSTAGLANDINS A;

EID: 0033817515     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
2. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514
3. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs
4. Overview of Phase II trials of MTA in solid tumors
5. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A Phase II study
6. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a Phase II study
7. MTA (LY231514) in combination treatment regimens using human xenografts and the EMT-6 murine mammary carcinoma
8. Clinical and pharmacokinetic Phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
9. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line
10. Extent of the requirement for folate transport by L1210 cells for growth and leukemogenesis in vivo
11. A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates
12. Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts
13. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo
14. Complementation of a methotrexate uptake defect in Chinese hamster ovary cells by DNA-mediated gene transfer
15. Acute lymphohlastic leukemia
16. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular structure and biological activity
17. Major facilitator superfamily
18. Rapid formation of poly-γ-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascited tumor cell in vitro
19. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line
20. A reduced carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate
21. Molecular analysis of murine leukemia cell lines resistant to 5,10-ideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase
22. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport
23. Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells
24. Transport energetics of the folic acid analogue, methotrexate, in L1210 cells: Enhanced accumulation by metabolic inhibitors
25. Energy-dependent efflux of methotrexate in L1210 leukemia cells. Evidence for the role of an ATPase obtained with inside-out plasma membrane vesicles
26. Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 cells
27. Inhibitory effects of prostaglandin A1 on membrane transport of folates mediated by both the reduced folate carrier and ATP-driven exporters
28. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function
29. Pattern of mutations that results in loss of reduced folate carder function under antifolate selective pressure augmented by chemical mutagenesis
30. Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier
31. Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells
32. Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carder function
33. Relationships be4tween carrier-mediated transport of folate compounds by L1210 leukemia cells: Evidence for multiplicity of entry routes with different kinetic properties expressed in plasma membrane vesicles
34. Preclinical cellular pharmacology of LY231514 (MTA): A comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells
35. Mechanism of action of methotrexate. IV. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Ehrlich ascites tumor cells in vitro
36. Methotrexate resistance in an L1210 cell line resulting from increased dihydrofolate reductase, decreased thymidylate synthetase activity, and normal membrane transport. Computer simulations based on network thermodynamics
37. The characteristics of the membrane transport of amethopterin and the naturally occurring folates
38. Recent advances in understanding of the mechanism of membrane transport of folates and antifolates
39. Multiple routes and regulation by tyrosine phosphorylation characterize the ATP-dependent transport of 2,4-dinitrophenyl S-glutathione in inside-out vesicles from human erythrocytes
40. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
41. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514
42. Augmentation of the therapeutic activity of lometrexol-(6-R)5,10-dideazatetrahydrofolate by oral folic acid
43. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate
44. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells
45. Carrier-mediated transport of the folic acid analogue methotrexate, in the L1210 leukemia cell
46. Increased activity of a novel low pH folate transporter associated with lipoplilic antifolate resistance in Chinese hamster ovary cells
47. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carder expression
48. Insertion of an intracisternal A particle within the 5'-regulatory region of a gene encoding folate-binding protein in L1210 leukemia cells in response to low folate selection. Association with increased protein expression